New combo therapy aims to control advanced lung cancer
NCT ID NCT07637448
First seen Jun 11, 2026 · Last updated Jun 17, 2026 · Updated 1 time
Summary
This study tests whether combining two types of drugs (EGFR-TKIs and a PD-1 antibody) can help control advanced non-small cell lung cancer with specific EGFR mutations. It involves 32 adults who have not had prior treatment. The main goal is to see how long the cancer stays under control before it progresses.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LUNG CANCER NON-SMALL CELL CANCER (NSCLC) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Southern Medical University Nanfang Hospital Department of Oncology
RECRUITINGGuangzhou, Guangdong, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.